Dr. King-Smith has worked in the pharmaceutical industry for the last 20 years, mainly in the field of topical prescription products. He helped establish fqubed, a company that pioneered the use of high throughput experimentation in the field of topical formulation development. fqubed was acquired by Nuvo Research in 2005. At Nuvo, Dominic served in executive positions in new product and strategic planning. He played a key role in developing Pennsaid 2%, currently the top selling topical product on the US market. Subsequently,he served as Crescita’s VP Corporate Development where he was responsible for out licensing the topical product Pliaglis to commercialization partners in the US and Europe. Dominic was appointed as EnZen’s CEO in April 2021. He holds BA and PhD in theoretical physics from Cambridge University. His scientific accomplishments include co-authoring two scientific journal papers with more than 1,000 citations and he is an inventor on 20 issued US patents.